Literature DB >> 2189315

HMB-45 antibody reactivity in pigmented lesions of the conjunctiva.

B J Glasgow1, L C McCall, R Y Foos.   

Abstract

Conjunctival pigmented lesions, including ten compound nevi, three subepithelial nevi, two acquired melanoses, and six melanomas, were examined histologically and immunohistochemically to determine the specificity of mouse monoclonal HMB-45 antibody for these lesions. Eleven of 13 nevi, two of two acquired melanoses, and six of six melanomas stained with this antibody. Conjunctival melanomas showed intense and diffuse cytoplasmic staining; compound nevi and subepithelial nevi showed less intense but diffuse reaction. There was strong staining in melanocytic cells at the junction of the epithelium and substantia propria in compound nevi and acquired melanoses. Unlike skin nevi, conjunctival nevi show HMB-45 reactivity in their stromal components. Immunoreactivity to HMB-45 does not distinguish benign from atypical or malignant melanocytic lesions of the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189315     DOI: 10.1016/s0002-9394(14)72438-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  C-myc oncogene expression in ocular melanomas.

Authors:  J A Royds; R M Sharrard; M A Parsons; J Lawry; R Rees; D Cottam; B Wagner; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

2.  Clinical and immunohistopathological study of conjunctival melanocytic lesions in pediatric and adolescent patients. A case series.

Authors:  Camelia Margareta Bogdănici; Claudia Florida Costea; Gabriela Florenţa Dumitrescu; Anca Sava; Delia Gabriela Ciobanu Apostol; Dragoş Viorel Scripcariu; Simona Delia Nicoară; Daniela Maria Tănase; Elena Corina Andriescu; Alexandru Cărăuleanu; Mihai Danciu; Silvia Cristina Sălăvăstru; Speranţa Schmitzer; Andrei Ionuţ Cucu; Irina Andreea Niagu
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.